Rheumatology

Your Article Summary

See Latest Articles

Can structural damage be prevented in ankylosing spondylitis
Current Opinion in Rheumatology, 06/12/09

Sieper J - A better understanding of the interaction between inflammation and new bone formation on the molecular level indicate that inflammatory molecules such as TNF-alpha inhibit osteoblasts and that a TNF-blockade induces new bone formation. Thus, TNF-blockers can only be expected to prevent new bone formation if this is coupled to inflammation and if inflammation is treated early enough. Studies on bone biomarkers in ankylosing spondylitis patients support the view that suppression of inflammation induces new bone formation.

Today in Bone Metabolism...keeping you current

Receive free subspecialty "5-minute updates" via email

Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09

Cardiovascular diseases and risk of hip fracture
JAMA, 10/23/09

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150mg and risedronate 150mg
Current Medical Research and Opinion, 10/22/09

See All of Bone Metabolism

Today in Spondylarthropathies...keeping you current

Receive free subspecialty "5-minute updates" via email

Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years drug survival
Rheumatology International, 10/14/09

Erythrocyte sedimentation rate, CRP level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis
Arthritis Care and Research , 11/02/09

Recreational Exercise in Rheumatic Diseases
International Journal of Sports Medicine, 10/30/09

See All of Spondylarthropathies